Work

A Case of Kras-mutated Jmml With High Methylation Profile and Perplexed Clinical Course.

Year: 2023
Type: article
Study design: Case Report
Abstract: Background and aims: JMML is a rare clonal hematopoietic malignancy of childhood. The deregulation of the RAS/MAPK signaling pathway caused in more than 90% of the cases by somatic or germline mutations in PTPN11, NRAS, KRAS, NF1, or CBL contributes to the pathogenesis of the disease. Clinical and molecular risk factors are used to stratify patients in risk groups and the treatment varies from watch-and-wait strategy to allogeneic bone marrow transplantation (HSCT), accordingly. The aim is to present a case with KRAS-mutated JMML, harboring unfavorable risk factors, determining his complicated course. Methods: A 3.5 year-old boy was diagnosed with JMML. Initial work-up revealed low platelets, elevated HbF(82%), normal karyotype and a KRAS mutation c.35 G>C;[p.G12A], VAF 41%. Results: The patient received 4 courses of azacitidine with no response (KRAS-VAF 33%) and he was transplanted from MSD(sister) with TreoFluTT regimen. First relapse with abnormal karyotype 49,XY(+4,+11,+2) occurred 12 months after 1stHSCT (KRAS-VAF 41%). Treatment with 3 cycles of azacitidine-venetoclax resulted initially to molecular response (KRAS-VAF<1%) that was sustained <3 months (KRAS-VAF28%). The patient underwent 2nd MSD-HSCT (brother) with BuMel regimen, 4 doses of prophylactic DLI and 4 cycles of venetoclax post-HSCT (KRAS-VAF<1%). Sixteen months after the 2ndHSCT, a 2nd relapse occurred with abnormal karyotype 46,XY,add(18), KRAS-VAF 31%. Therapy with FLA was administered to achieve molecular remission and a 3rd HSCT (MUD 10/10) was performed with BuFluTT regimen. The patient achieved complete remission and he is on maintenance with azacytidine (7thcycle) and ruxolitinib for GvHD. However, an unresolved severe pneumonia has recently occurred requiring mechanical ventilation. Conclusions: Somatic KRAS mutations account for 10-15% of JMML cases, usually with low/intermediate DNA methylation profile. However, in our case KRAS mutation was combined with exceptionally elevated HbF and high methylation profile, highlighting the crucial role of epigenetics also in KRAS-mutated cases as a determinant of the eventual disease phenotype and outcome. Keywords: JMML, KRAS, HSCT, high methylation profile
Language: English
Open Access status: gold
Estimated APC paid: $2,200
OpenAlex ID: W4389975403
FWCI:
Cites:
Cited by:
Related to: 10